26 June 2019 - Knight Therapeutics announced today that Knight's new drug submission for Ibsrela (tenapanor) has been accepted for review by Health Canada for the treatment of irritable bowel syndrome with constipation. 

Knight and Ardelyx entered into a license agreement in March 2018 granting Knight the exclusive right to commercialize tenapanor in Canada.

Tenapanor is an oral, first-in-class small molecule treatment under review by the FDA for the treatment of irritable bowel syndrome with constipation and is being evaluated in a second Phase 3 program for the treatment of hyperphosphatemia in patients with end-stage renal disease on dialysis.

Read Knight Therapeutics press release